Eli Lilly and Company $LLY Shares Sold by Prevail Innovative Wealth Advisors LLC

Prevail Innovative Wealth Advisors LLC decreased its position in Eli Lilly and Company (NYSE:LLY) by 95.4% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 367 shares of the company’s stock after selling 7,607 shares during the period. Prevail Innovative Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $394,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $25,000. Vermillion & White Wealth Management Group LLC lifted its position in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after buying an additional 16 shares during the last quarter. 10Elms LLP boosted its stake in Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after buying an additional 10 shares during the period. E Fund Management Hong Kong Co. Ltd. boosted its stake in Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after buying an additional 24 shares during the period. Finally, Miller Global Investments LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $33,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 2.3%

Shares of LLY stock opened at $1,041.89 on Friday. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95. The company has a 50 day moving average price of $941.52 and a 200 day moving average price of $1,003.33. The stock has a market capitalization of $981.19 billion, a P/E ratio of 37.01, a price-to-earnings-growth ratio of 1.11 and a beta of 0.48. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58. The company had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue was up 55.5% compared to the same quarter last year. During the same quarter last year, the company posted $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 35.82 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio (DPR) is 24.58%.

Wall Street Analysts Forecast Growth

LLY has been the topic of several recent analyst reports. TD Cowen upped their price objective on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Leerink Partners dropped their target price on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating for the company in a report on Monday, April 27th. Argus boosted their target price on Eli Lilly and Company from $930.00 to $1,200.00 and gave the company a “buy” rating in a research report on Monday, February 9th. CICC Research raised their price target on Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 11th. Finally, Rothschild & Co Redburn lifted their price objective on Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,219.26.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide, Lilly’s next-generation obesity drug, delivered strong Phase 3 results, with patients losing up to 28.3% of body weight over 80 weeks and as much as 30.3% over 104 weeks in an extension study. The data strengthens the drug’s commercial outlook and supports expectations for a future regulatory filing. Article Title
• Positive Sentiment: The company said retatrutide produced “meaningful” weight loss and appears to be a potential blockbuster in the fast-growing obesity market, adding to momentum behind Lilly’s already-strong GLP-1 franchise. Article Title
• Positive Sentiment: Lilly also announced a broad oncology showcase for the 2026 ASCO meeting, including Phase 3 data for Retevmo and Verzenio, plus updates from its acquired Kelonia Therapeutics and other cancer programs. That highlights pipeline breadth beyond obesity and could support longer-term growth expectations. Article Title
• Positive Sentiment: Several commentary pieces also argued that Lilly’s booming GLP-1 and obesity portfolio, including Mounjaro, Zepbound and Foundayo, keeps its growth story intact and may leave the stock with more upside.
• Neutral Sentiment: Lilly completed the acquisition of Engage Biologics for up to $202 million, adding non-viral DNA delivery technology to its genetic medicine platform. The deal is strategically constructive, but likely too small to move earnings near term. Article Title
• Neutral Sentiment: Lilly also raised $8.9 billion in debt, which increases financial flexibility for pipeline expansion and acquisitions, though it adds leverage. Article Title
• Negative Sentiment: One legal headline noted a lawsuit alleging a Trulicity rebate fraud scheme that cost Lilly more than $200 million. While not the main driver today, it could create some overhang if litigation expands. Article Title

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.